Valvular & structural heart diseaseCohort study
Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era
- Retrospective registry-based cohort study
- propensity-score matched
Authors' conclusion
Patients younger than 65 years had a high burden of comorbidities and incurred higher rates of death and readmission at 1 year compared to their older counterparts.
Study context
- Population
- Patients 80 years and younger undergoing balloon-expandable transcatheter aortic valve replacement (TAVR) (SAPIEN), STS/ACC Transcatheter Valve Therapy (TVT) Registry, August 2019 to September 2023
- Participants
- 139,695 patients
- Exposure
- Younger than 65 years vs Aged 65 to 80 years
- Younger than 65 yearsn = 13,849
- Aged 65 to 80 yearsn = 125,846reference
- Outcome
- Comorbidities and outcomes (death, stroke, hospital readmission)
Main finding
As reported in the abstract
Readmission and all-cause mortality · 1 year
| Group | Readmission | All-cause mortality |
|---|---|---|
| Younger than 65 years | 2740 [28.2%] | 908 [9.9%] |
| Aged 65 to 80 years | 23 178 [26.1%] | 6877 [8.2%] |
- Younger than 65 years vs Aged 65 to 80 years: P < 0.001 — readmission
- Younger than 65 years vs Aged 65 to 80 years: P < 0.001 — all-cause mortality
Observational data: associations, not effects.
Further findings
1-year readmission and all-cause mortality (propensity matched)
- Readmission, younger vs older patients (matched)
- 2732 [28.2%] vs 2589 [26.8%]; P < .03
- Mortality, younger vs older patients (matched)
- 905 [9.9%] vs 827 [10.1%]; P = .55
- propensity matched
Original publication
Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era. JAMA Cardiol. Published 1 February 2025. doi:10.1001/jamacardio.2024.4237
Summarised from the published abstract; every number is checked against it